Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 12/20 | 0.61 |
| ▸ | ACACA | Q13085 | 12/20 | 0.61 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
| ▸ | RARG | P13631 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12479133 | 0.90 | ACACB (0.64) | ACACBACACAMAPK14 | |
| SCHEMBL12479148 | 0.90 | ACACB (0.76) | ACACBACACAMAPK14RARBRARG | |
| SCHEMBL12029732 | 0.90 | ACACB (0.60) | ACACBACACATNKS2POLB | |
| SCHEMBL12029748 | 0.88 | ACACB (0.58) | ACACBACACATNKS2MAPK14POLB | |
| SCHEMBL12479480 | 0.87 | ACACB (0.79) | ACACBACACAMAPK14 | |
| SCHEMBL12456400 | 0.85 | ACACB (0.54) | ACACBACACATNKS2RXRA | |
| SCHEMBL12540243 | 0.84 | ACACB (0.79) | ACACBACACATNKS2 | |
| SCHEMBL2362779 | 0.84 | ACACB (0.59) | ACACBACACATNKS2 | |
| SCHEMBL12540088 | 0.84 | ACACB (0.66) | ACACBACACA | |
| SCHEMBL2353461 | 0.83 | ACACB (0.83) | ACACBACACARARBRARGRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000026-B2 | Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-07 | — | — | US | claimed |
| US-20140011853-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-09 | — | — | US | claimed |
| EP-2675788-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY | Bayer Intellectual Property GmbH (DE) | 2013-12-25 | — | — | EP | claimed |
| WO-2012110518-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-23 | — | — | WO | claimed |
| US-9000026-B2 | Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-9000026-B2 | Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-9000026-B2 | Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-8946124-B2 | Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy and halogen-substituted spirocyclic ketoenols | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946124-B2 | Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy and halogen-substituted spirocyclic ketoenols | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946124-B2 | Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy and halogen-substituted spirocyclic ketoenols | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20140045696-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY AND HALOGEN-SUBSTITUTED SPIROCYCLIC KETOENOLS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045696-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY AND HALOGEN-SUBSTITUTED SPIROCYCLIC KETOENOLS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045696-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY AND HALOGEN-SUBSTITUTED SPIROCYCLIC KETOENOLS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140011853-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-09 | — | — | US | disclosed |
| US-20140011853-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-09 | — | — | US | disclosed |
| US-20140011853-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-09 | — | — | US | disclosed |
| EP-2675788-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY | Bayer Intellectual Property GmbH (DE) | 2013-12-25 | — | — | EP | disclosed |
| WO-2012110518-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045696-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY AND HALOGEN-SUBSTITUTED SPIROCYCLIC KETOENOLS | DDT, PDHX, CYP8B1 | ACACB 904/4885ACACA 1096/4885TNKS2 4563/4885 |
| US-20140011853-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY | DDT, PDHA1, KCNH1 | ACACB 649/4885ACACA 866/4885TNKS2 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.